Fasting glucose: the single-moment number, the 70 to 99 range, and the hypoglycemia threshold in the labels

A fasting glucose is a photograph where the A1c is a time-lapse. It tells you what your blood sugar was at one moment, after at least eight hours without calories. On its own it is a noisier test than A1c. Next to an A1c it catches things the average hides, and it is usually free because it comes bundled in the comprehensive metabolic panel.

The ranges

MedlinePlus gives 70 to 99 mg/dL (3.9 to 5.5 mmol/L) as normal for a fasting sample, and notes that a random (non-fasting) result depends on when you last ate but is most often 125 mg/dL or lower. The ADA Standards of Care use fasting glucose as one of the diagnostic tests: 100 to 125 mg/dL is impaired fasting glucose (a form of prediabetes), and 126 mg/dL or higher, confirmed by a second test, meets the criterion for diabetes.

The MedlinePlus page carries the sentence you will see on every page of this site: normal value ranges may vary slightly among different laboratories. The range printed on your report is the one that applies to your sample.

Why a prescriber draws it before GLP-1 therapy

It corroborates the A1c. Anemia, kidney disease and hemoglobin variants can push an A1c away from the truth. A fasting glucose is not affected by any of those, so when the two disagree the prescriber knows to look harder.

It is already on the panel. Glucose is one of the fourteen tests in a comprehensive metabolic panel, which most prescribers order anyway for kidney and liver function. Booking the draw for the morning, fasting, turns that free glucose into a usable one.

It sets the low end. For people who take insulin or a sulfonylurea, the labels are explicit. The Wegovy label warns that concomitant use with insulin or an insulin secretagogue may increase the risk of hypoglycemia, including severe hypoglycemia, and that reducing the dose of those drugs may be necessary. In its type 2 diabetes trial (Study 3), hypoglycemia defined as plasma glucose under 54 mg/dL was reported in more patients on Wegovy than on placebo. The Zepbound label carries the same warning in section 5.7. A baseline glucose and a plan for home checks are how that warning turns into something practical.

How often it is repeated

No GLP-1 label sets an interval. For people with diabetes, the ADA Standards make A1c the routine measure and use glucose readings (fingerstick or continuous monitor) for day-to-day adjustment, especially when insulin is involved. For everyone else, a fasting glucose is repeated when the metabolic panel is repeated, which for most people on stable therapy means once a year unless something prompts an earlier draw.

Two situations prompt an earlier one. First, a low reading or symptoms of low glucose (shakiness, sweating, confusion) in someone on insulin or a sulfonylurea. Second, an A1c that does not fit the person: a surprisingly good result in someone who has become anemic, or a surprisingly high one in someone whose home readings look fine.

Reading the result

Three things move a fasting glucose that have nothing to do with diabetes: not actually fasting, acute illness or a steroid course, and the time the sample sat before it was spun (glucose keeps being consumed in the tube, so a delayed sample reads low). If a single result looks wrong, the answer is usually a repeat, not a decision.

What to discuss with your prescriber

• Whether your baseline panel should be fasting, and how long to fast.
• If you take insulin or a sulfonylurea: what the plan is for the first weeks, and what home reading should make you call.
• How your fasting glucose and A1c fit together, especially if one is normal and the other is not.
• What symptoms of hypoglycemia look like and what to keep on hand, if the warning applies to you.

For the labels' full warning lists by dose, the Semaglutide Hub and Tirzepatide Hub go through them arm by arm.